Employees: 37
Size Corvus Pharmaceuticals (CRVS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $860M, the 2320th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.19 on 18 Nov 2026.
Performance Over six months the shares fell 16.4%, against -22.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 19 in its peer set.
Short interest Short interest is 21.1% of the free float (30 Oct 2026).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$184,000 | -$105,000 | -$85,000 | -$151,000 | -$367,000 |
| EBITDA | -$67.6M | -$42.9M | -$27.5M | -$23.3M | -$32.2M |
| Net income | -$64.3M | -$15.3M | -$62.3M | -$27.0M | -$41.3M |
| Free cash flow | -$47.9M | -$33.0M | -$25.4M | -$24.0M | -$27.3M |
| Capital expenditure | $764,000 | $174,000 | $0 | $34,000 | $269,000 |
| Total debt | $632,000 | $937,000 | $1.12M | $1.37M | $2.60M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRVS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -10.5% | 6th highest of 21 |
| 6-month return | -16.4% | -22.8% | 9th highest of 19 |
| Distance from 52-week high | -62.2% | -40.2% | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |